Vaxcyte, Inc.
corporate_fare Company Profile
Vaxcyte, Inc. (NASDAQ:PCVX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for PCVX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PCVX spans 8-K, 424B5, FWP, 10-Q.
Recent high-impact activity:
- Vaxcyte's Q3 Loss Beats Estimates; VAX-31 BLA Filing Slated for 1H 2028
- Vaxcyte Posts $297M Q3 Loss, $3.4B Pro Forma Cash, OPUS-2/3 Data in 1H 2027
- Vaxcyte Closes Upsized $1.1B Concurrent Offerings After Full Over-Allotment Exercise
- Vaxcyte Finalizes $500M Equity Offering at $64/Share Alongside $500M Convertible Notes
- Vaxcyte Prices $1.15B Concurrent Offerings: $64/Share Common Stock and 1.50% Convertible Notes
Financial Snapshot
Short Interest & Short Volume
6.72 days to coverFINRA reported short interest of 15,359,758 shares in PCVX as of the October 30, 2026 settlement, a 5.0% increase from the prior period — about 6.7 days to cover at its recent average daily volume. On November 19, 2026, 84.0% of PCVX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for PCVX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-08.
Equity Offering Priced at $64.00/Share · Net Proceeds of ~$473M from Equity
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →